Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 5202 Reports

🤖 AI Analyzed

Recent

📄 Page 55 of 434

Transportation & Logistics Systems, Inc.

10-K March 30, 2026

Key Highlights

Company has transitioned into a shell entity following the sale or closure of al...
Management is actively seeking a new business purpose or acquisition to replace ...
The company has successfully separated from past liabilities by labeling former ...

Read Analysis

🤖 AI Generated

PDS Biotechnology Corp

10-K March 30, 2026

Key Highlights

PDS0101 entered a critical Phase 3 trial for head and neck cancer.
Positive Phase 2 results demonstrated superior performance over standard care.
Engaged with the FDA for an 'Accelerated Approval' pathway to expedite market en...

Read Analysis

🤖 AI Generated

BGSF, INC.

10-K March 30, 2026

Key Highlights

Strategic pivot to focus exclusively on the $1.5 billion property management sta...
Debt-free balance sheet following the $35 million sale of the Professional divis...
Active exploration of strategic alternatives, including potential sale or merger...

Read Analysis

🤖 AI Generated

TechCom, Inc.

10-K March 30, 2026

Key Highlights

Majority shareholder Aziz Ali has committed to funding all operating costs throu...
The company is actively seeking a merger with a private entity to establish acti...
Management is specifically targeting stable, growing companies for potential acq...

Read Analysis

🤖 AI Generated

BOSTON OMAHA Corp

10-K March 30, 2026

Key Highlights

Revenue grew to $112.4 million in 2025, driven by broadband expansion.
Company initiated a $30 million share buyback program, signaling management conf...
Strategic shift toward owning and operating infrastructure like fiber networks a...

Read Analysis

🤖 AI Generated

Firsthand Technology Value Fund, Inc.

10-K March 30, 2026

Key Highlights

Provides retail investors access to early-stage, private technology companies ty...
Deep involvement in portfolio companies through debt and equity financing.
Long-term growth strategy focused on exit events like IPOs or company sales.

Read Analysis

🤖 AI Generated

CIM REAL ESTATE FINANCE TRUST, INC.

10-K March 30, 2026

Key Highlights

Successful portfolio pruning with $415 million in asset sales to reduce debt and...
Strong property management with a high 96.5% occupancy rate across 18.5 million ...
Strategic pivot toward becoming a pure-play real estate lender with $600 million...

Read Analysis

🤖 AI Generated

Aura Biosciences, Inc.

10-K March 30, 2026

Key Highlights

Lead drug candidate bel-sar showed 80% tumor control in Phase 2 eye cancer trial...
90% of patients in clinical trials maintained their vision, outperforming curren...
FDA 'Fast Track' status granted for the company's bladder cancer program.

Read Analysis

🤖 AI Generated

Glucotrack, Inc.

10-K March 30, 2026

Key Highlights

Successfully completed first human study with clinically accurate results.
Achieved ISO 13485:2016 certification for manufacturing quality.
Strategic pivot to U.S. market with FDA pre-submission package finalized.

Read Analysis

🤖 AI Generated

Annexon, Inc.

10-K March 30, 2026

Key Highlights

Successful Phase 3 trial for Tanruprubart (ANX005) in Guillain-Barré Syndrome.
Large-scale Phase 3 trial for Vonaprument (ANX007) in dry AMD with results expec...
Strong cash position of $365.4 million, providing runway into the second half of...

Read Analysis

🤖 AI Generated

STANDARD LITHIUM LTD.

40-F March 30, 2026

Key Highlights

Completed a study for the South West Arkansas project, estimating a $1.5 billion...
Successfully validated Direct Lithium Extraction (DLE) technology at a 50 gallon...
Strategic focus on three major projects to position the company as a key U.S. li...

Read Analysis

🤖 AI Generated

Akari Therapeutics Plc

10-K March 30, 2026

Key Highlights

Strategic acquisition of Peak Bio, Inc. adds Phase 2-ready oral drug PHP-303 to ...
Diversified research portfolio now includes both nomacopan and PHP-303, targetin...
Transitioning from rare disease focus to larger market inflammatory and autoimmu...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage